Summary of China Cosmetics Conference Call Industry Overview - The focus is on the **anti-aging beauty market** in China, which includes traditional anti-aging skincare, medical aesthetics (MA), and dermocosmetics. - The market is expected to grow at a **high single-digit CAGR** over the period from 2025 to 2030, with medical aesthetics and dermocosmetics leading at **9%** and anti-aging skincare at **6%** [1][22]. Key Insights Market Penetration and Demographics - The current penetration of the MA market in China is low, estimated at **5%** for the core consumer group aged **20-60**, compared to **10%-20%** in developed markets. It is expected to rise to **8%** by **2030E**, supporting a **10% CAGR** for MA users [2][22]. - Anti-aging skincare is seeing earlier adoption among younger consumers, with approximately **40%** of this demographic engaging with the category, which is expected to drive further expansion [2][22]. Pricing Dynamics - More resilient pricing is anticipated from **2026E** due to stricter regulations and healthier competition, with limited supply tailwinds favoring recombinant collagen. The MA market has experienced sharp price reductions due to intense competition, but future pricing is expected to stabilize [3][22]. - Factors contributing to this stabilization include more accessible pricing in China and a narrower price gap with Korea following recent policy changes [3][22]. Company Recommendations - **Forest Cabin** is initiated with a **Buy** rating, expected to benefit from growth in oil-based anti-aging skincare, with a projected **48% sales CAGR** from **2022-2025E** and **32%/29% sales/NP CAGR** from **2025-2028E** [4][22]. - **Giant Biogene** is also rated **Buy** due to its integrated value chain from MA to dermocosmetics, enhancing R&D and brand recognition [4][22]. - **Proya** is viewed as a domestic leader in the anti-aging sector but is rated **Neutral** pending further evidence of the new management's execution track record [4][22]. Market Growth Projections - The overall anti-aging market in China is projected to grow from **RMB 214 billion** in **2024E** to **RMB 398 billion** by **2030E**, reflecting a **CAGR of 8%** [20][22]. - Medical aesthetics is expected to contribute significantly to this growth, with a **10.3% volume CAGR** over the same period, despite ongoing pricing pressures in certain categories [17][22]. Additional Insights - The report emphasizes the importance of companies with larger sales exposure to growth segments, stronger market positions, and better operational execution, including R&D capabilities [10][22]. - The anti-aging skincare segment is projected to see a shift towards functionalities beyond basic moisturizing, with penetration expected to increase from **25.6% to 29.0%** from **2025 to 2030E** [19][22]. Conclusion - The anti-aging beauty market in China presents significant growth opportunities driven by demographic shifts, evolving consumer perceptions, and technological advancements. Companies like Forest Cabin and Giant Biogene are well-positioned to capitalize on these trends, while pricing dynamics and market penetration will play crucial roles in shaping the competitive landscape.

Summary of Conference Call Records Industry Overview - **Consumer Sector**: The consumer sector, particularly mass dining and service consumption, continues to show a recovery trend. High-end consumption, including luxury goods and high-end jewelry, is performing even stronger, with some indicators exceeding expectations, reflecting a structural recovery in the consumer market [1][2]. Key Insights and Arguments - **Travel and Hospitality**: The travel chain significantly benefited from the longest Spring Festival in history, with hotel Average Daily Rate (ADR) increasing. Family travel demand is prominent, driven by the return home trend, quality scenic dining, and "reverse New Year" celebrations in first-tier cities [1][2]. - **Luxury Goods and Jewelry**: There is a clear differentiation in jewelry and luxury goods consumption, heavily influenced by high gold prices. Luxury goods consumption is relatively stronger, with high-end shopping district data exceeding expectations. The focus is on brand share improvement opportunities, as some brands are pressured by gold prices, creating structural opportunities for share changes [1][3]. - **Medical Aesthetics**: During the Spring Festival, medical aesthetics saw a double-digit increase in customer flow, although average prices were under pressure. Products like collagen water light and related offerings are expected to benefit from a robust pipeline and expanding market size. High-demand categories are likely to continue benefiting, necessitating tracking of certification rhythms and profit balance in the supply chain [1][3]. - **Cosmetics Sector**: The cosmetics sector is expected to see an upward trend around the March 8th node. Notable performance was observed in the China Resources system, particularly with the brand Mao Ge Ping. The investment strategy leans towards "momentum varieties" and "bottom stocks with share improvement," focusing on key companies [1][4]. Additional Important Insights - **Export Chain Dynamics**: The export chain is expected to see excess growth driven by "new products + new capacity deployment." The short-term key factor is the RMB exchange rate, which influences month-on-month changes. Companies with new capacity or product lines are prioritized for attention [2][4]. - **Tobacco Sector Changes**: The tobacco sector is undergoing significant changes due to adjustments in the international system by China National Tobacco. The removal of intermediaries in the domestic duty-free market is expected to enhance profits by approximately 3-5 percentage points [5]. - **Carbon Trading Opportunities**: The importance of carbon trading is increasing, driven by initiatives in Europe and the introduction of carbon tax mechanisms in domestic industries like steel and cement. Companies involved in carbon trading development, such as Yueyang Forest Paper and Yong'an Forestry, are worth monitoring for new business growth opportunities [6]. - **Pork Price Trends**: As of February 26, 2026, the average price of pork is approximately 10.7 CNY/kg, down 1 CNY from pre-Spring Festival levels. The market is expected to stabilize between 10.5-11.5 CNY/kg in the coming months, supported by potential state stockpiling and market entry by new players [10][11]. Investment Recommendations - **Consumer Sector**: Focus on the restaurant chain as a core direction, recommending companies like Anjiu and Yihai, while also considering those with accelerated store opening expectations. The snack sector remains promising, particularly in volume sales channels, with companies like Weilong and Salted Fish being highlighted for their investment value [14]. - **Medical Aesthetics and Cosmetics**: Companies with robust pipelines and market expansion potential should be closely monitored, particularly in the medical aesthetics sector [3][4]. This summary encapsulates the key points from the conference call records, providing insights into the consumer sector's recovery, investment opportunities, and market dynamics.

行 业 及 产 业 美容护理 2026 年 03 月 01 日 行 业 研 究 / 行 业 点 评 相关研究 证 券 研 究 报 告 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 王立平 A0230511040052 wanglp@swsresearch.com 38 大促进行时，国货经典大单品合作超头主播 看好 ——化妆品医美行业周报 20260301 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 博时基金 博时基金管理有限公司(researchreport@bosera.com) 使用。1 - ⚫ 本阶段化妆品医美板块表现弱于市场。2026 年 2 月 6 日至 2026 年 2 月 27 日期间， 申万美容护理指数下滑 0.9%，表现弱于市场。其中，申万化妆品指数下滑 0.9%，弱于 申万 A 指 4.9pct；申万个护用品指数上涨 2 ...

行业研究丨深度报告丨零售业 [Table_Title] 化妆品掘金增长系列：品类视角拆解竞争格局 %% %% %% %% research.95579.com 1 丨证券研究报告丨 报告要点 [Table_Summary] 我们认为对美妆竞争格局的判断，如细致拆解为品类和渠道，则可得出两方面结论：其一，对 于已建立领先优势的品牌，乳液面霜、面部精华为其品类基本盘，前者头部效应显著、后者更 易实现品类间连带；天猫为其渠道基本盘，在该渠道占据头部地位的品牌公司更易实现"强者 恒强"。其二，对于寻求增量、力求拓品类的品牌，抖音渠道尚处格局成长期，更易依托运营及 产品力实现排名突破。 分析师及联系人 [Table_Author] SAC：S0490514080004 SAC：S0490520080019 SFC：BUV258 请阅读最后评级说明和重要声明 2 / 20 %% %% %% %% research.95579.com 2 李锦 罗祎 曾维朵 [Table_Title2] 化妆品掘金增长系列：品类视角拆解竞争格局 [Table_Summary2] 总量：行业增速平稳，核心品类仍具国产化空间 护肤行业增速平稳 ...

商贸零售 2026 年 03 月 01 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -24% -12% 0% 12% 24% 36% 2025-03 2025-07 2025-11 商贸零售 沪深300 相关研究报告 《马年春节消费稳健恢复，老铺黄金 宣 布 2 月 底 调 价 — 行 业 周 报 》 -2026.2.23 投资主线一（黄金珠宝）：关注具备差异化产品力和消费者洞察力的黄金珠宝品 牌，重点推荐潮宏基、老铺黄金、周大福等，受益标的周生生等； 投资主线二（线下零售）：关注顺应趋势变革探索的线下零售企业和 AI 赋能跨 境电商龙头，重点推荐永辉超市、爱婴室、吉宏股份、赛维时代等； 投资主线三（化妆品）：关注满足情绪价值和安全成分创新的国货品牌，重点推 荐毛戈平、珀莱雅、上美股份、巨子生物、润本股份，受益标的林清轩等； 投资主线四（医美）：关注差异化医美产品厂商和持续并购扩张的连锁医美机构， 重点推荐美丽田园医疗健康、爱美客、科笛-B、朗姿股份等。 《美团拟收购叮咚买菜，打造即时零 售供应链优势—行业周报》-2026.2.8 《功效护肤品牌 HBN 母公司护家科 技递表港交所—行业周报》-2 ...

商贸零售 2026 年 03 月 01 日 投资评级：看好（维持） 行业走势图 数据来源：聚源 -24% -12% 0% 12% 24% 36% 2025-03 2025-07 2025-11 商贸零售 沪深300 相关研究报告 《马年春节消费稳健恢复，老铺黄金 宣 布 2 月 底 调 价 — 行 业 周 报 》 -2026.2.23 《美团拟收购叮咚买菜，打造即时零 售供应链优势—行业周报》-2026.2.8 《功效护肤品牌 HBN 母公司护家科 技递表港交所—行业周报》-2026.2.1 老铺黄金调价幅度超预期，巩固品牌高端调性 ——行业周报 | 黄泽鹏（分析师） | 李昕恬（联系人） | | --- | --- | | huangzepeng@kysec.cn | lixintian@kysec.cn | | 证书编号：S0790519110001 | 证书编号：S0790125100021 | 老铺黄金调价幅度超预期，巩固品牌高端调性 2 月 28 日老铺黄金启动 2026 年首次调价，多数产品涨幅集中在 20%至 30%区间， 对比 2025 年三次调价，提价幅度明显放大。调价落地前，提价预期叠加大 ...

Key Takeaways EL posted 6% organic Skin Care sales growth in Q2, among its strongest categories. Strength in Mainland China and brands like Estee Lauder and La Mer drove gains.Better inventory alignment and improved Asia/Pacific retail trends aided resilience.The Estee Lauder Companies’ (EL) Skin Care remained a key bright spot in second-quarter fiscal 2026, supported by stronger retail trends in select markets. Performance in Mainland China and continued brand momentum helped steady the category amid an ev ...

"报告期内，公司围绕皮肤科学创新转化业务和营养科学创新转化业务开展系统性结构优化，对相关业 务对应的C端品牌体系、产品结构及渠道模式进行调整"，华熙生物表示，公司压缩了以销售额为单一 指标的投放活动，减少部分投入产出效率较低的品牌及项目。 这种"增利不增收"的矛盾表象，除了上年同期比较基数较小和非经常性损益的影响，根源或在于华熙生 物"降本"。 业绩快报显示，报告期内，华熙生物归属于母公司所有者的净利润、归属于母公司所有者的扣除非经常 性损益的净利润同比增加达30%以上，主要系公司持续优化业务结构和资源配置，销售费用及管理费用 同比减少所致。 具体来看，2025年，华熙生物的管理费用同比下降超过10%，销售费用同比下降超过30%。 新京报贝壳财经讯(记者李铮)2月27日，玻尿酸巨头华熙生物科技股份有限公司(以下简称"华熙生物")发 布2025年度业绩快报。 报告期内，华熙生物实现营业总收入42.17亿元，与上年同期的53.71亿元相比减少了21.49%；归属于母 公司所有者的净利润2.91亿元，同比增加67.03%；归属于母公司所有者的扣除非经常性损益的净利润同 比增加了75.28%至1.88亿元。 据新京报 ...

北京商报讯（记者 王寅浩 宋雨盈）2月27日，华熙生物发布2025年业绩快报，2025年度公司实现营业总 收入42.17亿元，比上年同期下降21.49%；实现归属于母公司所有者的净利润2.91亿元，比上年同期增 加67.03%；实现归属于母公司所有者的扣除非经常性损益的净利润1.88亿元，比上年同期增加75.28%。 业绩快报显示，业绩变动主要系公司持续优化业务结构和资源配置，销售费用及管理费用同比减少所 致。 ...

2 编号：2026-003 投资者关系活 动类别 ☑ 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称 及人员姓名 工银瑞信基金管理有限公司 秦聪 马丁 国海证券股份有限公司 李宇宸 时间 2026 年 2 月 27 日 15：00-15：40 地点 电话会议 上市公司接待 人员姓名 邓百娇女士 董事、董事会秘书 吴 弘先生 证券事务代表 齐鑫鑫女士 投资者关系管理 IR 投资者关系活 动主要内容介 绍 Q1、请简要介绍一下公司的产品结构情况。 A：目前公司产品主要分为医疗器械类产品与功能性护肤 品两大板块，从剂型上主要分贴片类与非贴片类，非贴片类涵 盖水、精华、乳液、喷雾、冻干及次抛精华等多种形态。 Q2、公司非贴片类产品占比情况如何？ A：上海研发中心成立后，我们在化妆品产品方面上新速 度持续加快，产品与剂型不断丰富，在产品结构进一步完善的 同时，非贴片类产品的收入占比也在不断提升。 Q3、公司的三类医疗器械产品进展情况如何？ A：目前我们进展比较快的主要是重组Ⅲ型人源化胶原蛋 白冻干纤维、重组Ⅲ型人源化胶原蛋白贴 ...